Lancet Haematol
Bexmarilimab plus azacitidine for high-risk MDS and relapsed or refractory AML
Kontro M, Stein AS, Pyörälä M, et al
This study was designed to determine the safety of bexmarilimab plus standard-of-care treatment in MDS and AML, and to identify the recommended dose for expansion of bexmarilimab in combination with standard of care. In this study, the authors demonstrated that the combination of bexmarilimab with azacitidine had a manageable safety profile, consistent with azacitidine, and promising clinical activity.
Previous Article
- • Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study
- • Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML
- • Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia
- • Integrative genomic and immune profiling to identify and characterize high-risk subgroups in AML: development of a 20-gene predictive signature
- • Targeting p16INK4a-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven AML
- • Gilteritinib in FLT3-mutated AML: a real-world Italian experience
- • Decitabine combined with reduced-intensity conditioning for older patients with AML in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation
- • Prognostic covariates associated with outcomes in patients with NPM1-mutated AML
- • Venetoclax combined with azacitidine in elderly AML
- • Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory AML
- • Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML
- • Bexmarilimab plus azacitidine for high-risk MDS and relapsed or refractory AML
- • Comparison of consolidation strategies for pediatric patients with AML
- • Molecular monitoring versus standard clinical care in younger adults with AML
- • A phase 2 trial of geriatric assessment-guided selection of treatment intensity in older adults with AML
